New heart failure drug enters early safety testing
NCT ID NCT07218627
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 22 times
Summary
This early-stage study tests a new drug called NNC0537-1482 in 36 adults with heart failure. The main goal is to check if the drug is safe and how the body processes it. Participants are randomly assigned to receive either the drug or a placebo, and neither they nor the doctors know who gets which. The study lasts up to 64 days, plus a screening period.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Richmond Pharmacology
RECRUITINGLondon, SE1 1YR, United Kingdom
Conditions
Explore the condition pages connected to this study.